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| INTRODUC TI ON
Acute myeloid leukemia (AML) is a life-threatening malignancy characterized by the unlimited expansion and blockade of differentiation of hematopoietic stem/progenitor cells (HSPCs). 1 Heterogeneity of AML is manifested by multiple oncogenic proteins, including mixed-lineage leukemia (MLL) fusions/t(v;11q23), PML-RARα/t(15;17), AML1-ETO/t(8;21) and CBFB-MYH11/ (inv16).
2,3 AML with MLL rearrangement/t(v;11q23) is a specific subtype due to its poor clinical prognosis. The MLL gene encodes a H3K4 methyltransferase that is critical for development and hematopoiesis. Chromosomal rearrangements involving the MLL gene are associated with high-risk infant, pediatric, adult and therapyinduced acute leukemia. 4, 5 To date, over 79 different MLL fusions have been identified in acute leukemia patients. 6 The most common MLL fusion partners include AF4, AF9, ENL, AF10 and ELL, which together account for over 80% of MLL-rearranged AML 7, 8 and 4% of all AML patients. 9 These most recurrent MLL fusions share a similar downstream pathway, including aberrant upregulated expression of MLL target genes and histone modification genes, as shown by several studies. [10] [11] [12] [13] [14] Studies have demonstrated that enforced expression of MLL-
AF9 fusion protein could transform the non-self-renewing granulocyte/macrophage progenitors (GMP) into leukemia stem cells (LSC)
by activating the expression of Hox proteins. 15 Consistently, the co- and Six-domain (SD, 110-115 amino acids). 20 Six1 plays an important role in the development of several organs. 21 Six1-knockout (KO) mice die shortly after birth and KO embryos show defective development in several organs and tissues. [22] [23] [24] [25] Six family members could mediate the DNA-binding specificity and transcriptionally activate their target genes via the recruitment of EYA protein, which contains transactivation and phosphatase domains. 26, 27 Six1 is overexpressed in various cancers, such as breast cancer, liver cancer and colorectal cancer. 21, [28] [29] [30] [31] Importantly, increased SIX1 expression predicts poor clinical outcomes in solid tumors. 21 Although Six1 alone cannot transform HPC, it was shown to collaborate with Eya1 in hematopoietic transformation assays in vitro. 30 In addition to its role in leukemia initiation, the specific role of Six1 in leukemia progression remains unexplored.
In the present study, we demonstrated that Six1 is overexpressed in several AML, and its high expression is significantly correlated with a poor prognosis. The specific functional role of Six1 in leukemia maintenance in vivo and in LSC pool maintenance, as well as the underlying mechanism were also explored. 
| MATERIAL S AND ME THODS

| Mice
| Generation of scramble and Six1 knockdown leukemia mouse models
For lentivirus production, 293T cells were transfected with shRNA containing SF-LV-BFP plasmids and the helper plasmid pMD.G and psPAX2 with Lipofectamine 2000. Virus-containing supernatant medium was collected 2 days after transfection. MLL-AF9 leukemia cells 32 were pre-stimulated overnight with 10 ng/mL of mIL3 and mIL6 and 50 ng/mL of mSCF (Peprotech, Rocky Hill, NJ, USA) and were then transduced with scramble or shRNA lentivirus supernatant. After 2 days of culture, the transduced cells were collected and transplanted into lethally irradiated (9.5 Gy) mice.
| Colony-forming unit assay
Cells were placed in M3231 (Stem Cell Technologies, Vancouver, Canada) methylcellulose with 10 ng/mL of mIL3, 10 ng/mL of mIL6, 10 ng/mL of GM-CSF, 50 ng/mL of SCF (Peprotech), and 50 U/mL of penicillin/streptomycin (Gibco, Invitrogen, Grand Island, NY, USA) and were then plated in 24-well plates to ensure 500 cells per well.
The colonies were counted after 7 days of culture.
| Flow cytometry, apoptosis and cell cycle analysis
Bone marrow cells were flushed with 2 mmol/L EDTA and 2% FBS containing PBS and were then stained with antibodies at the appropriate proper dilution (Table S1 ). 
| Western blotting analysis
Bone marrow leukemia cells were lysed with RIPA buffer and then were resolved by 10% SDS-PAGE and transferred to a PVDF membrane (Merck Millipore, Carrigtwohill, Ireland), as previously described. 35 The antibodies used are listed in Table S1 .
| qRT-PCR
Total RNA was extracted using the RNeasy Kit (QIAGEN, Hilden, Germany), and cDNA was synthesized using the PrimeScript RT Reagent Kit with gDNA Eraser (TAKARA, Kusatsu, Japan) according to the manufacturer's instructions. Quantitative RT-PCR was performed in triplicate using a QuantStudio 5 (ThermoFisher, Singapore) and the Fast SYBR Green Master Mix (Roche, Mannheim, Germany), as previously described. 36 All primers used in this study are listed in Table S2 . 
| Pyruvate assays, lactate assays and ATP assays
| Histology analysis
Tissue samples were fixed in 4% formaldehyde for over 12 hrs, embedded in paraffin, sectioned at 8-μm thickness and then stained with H&E as previously described. spleen and bone marrow were considered to be non-responders.
The frequencies of LSC were calculated according to Poisson statistics using ELDA software. 37 The χ 2 -test was employed (*P < 0.05, **P < 0.01).
| Statistical analysis
Student's t test was used to compare the 2 groups. One-way ANOVA was used to compare more than 2 groups. The absence of * in the graphs indicates no significant difference between the groups.
Analyses were carried out using GraphPad Prism 7.
| RE SULTS
| High expression of SIX1 predicts a poor prognosis in acute myeloid leukemia patients
To explore the potential role of SIX1 in leukemia, we assessed its expression pattern in the existing clinical databases (the HemaExplorer database). 38 We found that SIX1 was highly expressed in AML cells in patients compared with that in granulocyte-macrophage progenitors (GMP) ( Figure 1A ), which are considered a major cell type that contributes to malignant transformation and leukemia maintenance in MLL fusion leukemia. 16 We noticed that AML with MLL Furthermore, we found that in the MLL-r group, the patients with high expression levels of SIX1 have a tendency of worse survival ( Figure 1F ). However, in the non-MLL-r group, the survival curve was similar between Six1-high and Six1-low groups ( Figure 1G ). These data indicate that SIX1 may play an important role in MLL-r leukemia maintenance and/or progression.
| Establishing the Six1-knockdown acute myeloid leukemia murine model
To further investigate that the high level of Six1 is essential for leukemia maintenance, we reduced Six1 expression in MLL-AF9 leukemia models using a lentivirus-shRNA-mediated knockdown (KD) system. Figure S1 ). Taken together, we conclude that the knockdown of Six1 suppressed leukemia progression and prolonged AML mouse survival with reduced leukemia blast cell burden. 
| Six1 knockdown decreases the frequency and absolute number of leukemia stem cells
| Six1-KD increases cell apoptosis and changes the glycolytic gene expression
To further explore the underlying cellular mechanisms that might contribute to there being fewer LSC, we analyzed the apoptosis ratio and cell cycle of LSC in Six1-KD and control groups. As shown in Figure 5A -C, the LSC showed both increased early apoptosis and late apoptosis in the Six1 KD groups compared with that in the control group. Consistently, a higher protein level of activated Caspase 3 (cleaved Caspase 3) was observed in Six1-KD cells ( Figure 5D ). For A-D, the leukemic cells were collected from the femur, tibia and ilium, and live cells were counted with trypan blue exclusion; For A-F, n = 5, 2 independent experiments; mean ± SD; one-way ANOVA, **P < 0.01; ***P < 0.001. G, Colony-forming assay of leukemic BM cells. In total, 500 live cells were plated per well in a 24-well plate. n = 4, mean ± SD; one-way ANOVA, *P < 0.05; **P < 0.01; ***P < 0. In addition, we found that G0, G1 and S/G2/M phases with Ki67
and Hoechst staining were similar between the Six1-KD and control groups ( Figure S3A,B) . Although increased expression of p21, a key suppressor of the cell cycle, 42 and decreased expression of Ccnd1, a classic Six1 target, 43, 44 were observed, most of the cell cycle regulators examined remained unaltered between the Six1-KD and control groups ( Figure S3C ). In addition, the expression of classic targets of MLL-AF9, such as Hoxa9, Hoxa10 and Meis1, remained unchanged ( Figure 5E ).
Because recent reports showed that Six1 functions as a key upstream regulator of glycolysis, and thus regulates solid tumor survival, 44 we next analyzed the expression of glycolytic genes in Six1-KD AML cells. Consistent with their findings, we also detected a reduction in the expression of glycolytic genes ( Figure 5F ) as well as a decrease in cellular levels of pyruvate and lactate in Six1-KD AML cells ( Figure 5G and Figure S4A ). However, the cellular level of ATP was similar between scramble and Six1-KD groups ( Figure S4B ).
Taken together, these data suggest that Six1 maintains the number of functional LSC by anti-apoptosis and blockage of differentiation, possibly mediated by regulating glycolysis.
| D ISCUSS I ON
In this study, we characterized the biological role of Six1 in regulating AML progression in vivo. Homeodomain-containing transcription factor Six1 was reported to be expressed in various tissues throughout embryogenesis. 21 Moreover, Six1 is overexpressed in For panels E-G, n = 3, one-way ANOVA, *P < 0.05; **P < 0.01; ***P < 0.001 various solid tumors, such as cervical cancer, 31,45 hepatocellular carcinoma 28, 44 and Wilms tumors. 46, 47 We also observed the highly increased expression of Six1 in AML patients, especially in MLL-rearranged AML. Taken together, these studies suggest an oncogenic role of Six1 in various cancers. In addition, SIX1 was reported to be correlated with a poor prognosis in several cancers. Here, we found that high expression of SIX1 predicts a poor prognosis in AML patients, implicating an independent role of SIX1 as a biomarker for poor outcome prediction.
To further explore the role of Six1 in leukemia progression, we established a Six1-knockdown AML murine model. We observed a significantly prolonged survival of leukemia mice with Six1 KD.
Compared with control mice, Six1-KD leukemia mice showed reduced numbers of peripheral white blood cells, mild relief of anemia and thrombocytopenia, and less tissue infiltration, accompanied with more differentiated leukemia blast cells in BM, suggesting an overall reduction of the leukemia cell burden.
As has been shown previously, leukemia initiation and maintenance were driven by LSC. The existence of LSC is also responsible for the relapse and drug resistance. In consideration of this, the number and function of LSC in Six1 KD mice were further examined. The frequency and cellularity of both c-Kit + and L-GMP cells were both decreased with Six1 KD compared with those of controls.
Moreover, Six1 KD significantly reduced the overall number of type A colonies in colony-forming unit assays that were used to estimate the myeloid clonogenic ability of LSC. 40, 41 In addition, our limiting dilution assay confirmed that the frequency of functional LSC were significantly reduced by approximately fourfold with Six1-KD. These data demonstrated that Six1 regulates leukemia progression through maintenance of the frequency of functional LSC.
Further investigation of the mechanism of reduced LSC numbers revealed that both increased LSC apoptosis and induction of differentiation may contribute to the phenotypes in the Six1-KD mouse model. However, it is difficult to discern which of the 2 biological changes has a more significant role in repressing LSC, and further mechanistic studies are required to answer this question. Cell cycle regulation had no obvious contribution in regulating LSC numbers.
The G1/S phase depends on cyclin D1 and cyclin E and is negatively regulated by the cyclin-dependent kinase inhibitor p21, which is associated with cell cycle arrest in the G1 phase. 42, 48 Although the expression of Ccnd1, a classic target of Six1, is downregulated, and the cell cycle blocker p21 is upregulated in Six1 KD mice, the cell cycle was similar between control and Six1 KD groups. This might be due to the slight increase of Ccne1, which could promote the G1 to S phase transition.
Aberrant glucose metabolism has now been widely accepted as a hallmark of cancer, as characterized by the high level of glycolysis even in the presence of abundant oxygen. 49 In addition to the transcription factor hypoxia-inducible factor 1 α (HIF-1α) [50] [51] [52] and oncogenic factor c-Myc, [53] [54] [55] [56] Six1 is a newly characterized transcription factor that regulates glycolysis in solid tumors. 44 It was shown that SIX1 directly binds to the promoter region of most glycolytic genes and increases the expression of these genes in solid tumors, thus promoting glycolysis and tumor growth in vitro and in vivo. 44 Increased glycolysis is overall observed in multiple hematological malignancies, 57 including AML, 58 ALL, 59 CLL 60 and multiple myeloma. 61 In AML, highly glycolytic AML blasts were more resistant to apoptosis induced by chemotherapeutic drugs ARTA (all-trans-retinoic acid) and/or ATO (arsenic trioxide) in vitro, suggesting potential resistance to induction chemotherapy. 58 Deletion of either pyruvate kinase isoform (PKM2) or lactate dehydrogenase A (LDHA), both of which catalyzed the final steps in glycolysis, could significantly attenuate the initiation and maintenance of murine CML and AML. 62 In our study, we found that Six1 also plays a role in regulating glycolysis in AML. We observed significant changes in the glycolytic gene expression and decreased cellular levels of pyruvate and lactate in Six1-KD AML mice. However, to our surprise, the ATP level between scramble and Six1-KD cells was similar, suggesting that ATP production might be compensated by oxidative phosphorylation in Six1-KD AML cells. 63 These observations indicate that Six1 may provide a carbon source for leukemia cells through aerobic glycolysis.
However, further investigation is needed for Six1 in glycolysis in relation to leukemia progression.
Taken together, Six1 is not only differentially expressed during normal hematopoiesis or leukemogenesis but is also a key transcription factor that regulates LSC pools and the expression of glycolytic genes. Thus, it may be a good choice as a therapeutic target in AML treatment.
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